Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

H2-Pharma and CHEPLAPHARM Announce Re-Launch of XENICAL® Capsules


MONTGOMERY, Ala., Jan. 3, 2018 /PRNewswire/ -- H2-Pharma, LLC, a privately held pharmaceutical company, announced today that it has re-launched XENICAL® (orlistat) 120 mg Capsules via its newly formed Branded division. This opportunity arose due to the partnership with CHEPLAPHARM Arzneimittel GmbH, who has recently completed its acquisition of XENICAL® from F. Hoffman-La Roche/Genentech, and has agreed to give H2-Pharma the exclusive distribution rights to market XENICAL® in the U.S.

H2-Pharma Logo

XENICAL®, indicated for obesity management, received marketing approval from the U.S. Food and Drug Administration in 1999, and is the only prescription Orlistat product in the U.S. 

H2-Pharma's President, Bryce M. Harvey said, "We are excited to re-launch XENICAL® as it represents the first branded product that H2-Pharma has brought to the U.S. market. Our brand strategy is to seek out underserved products that have the potential to grow with the right focus and commercialization efforts. XENICAL® is an established brand that is reflective of the type of branded products we are seeking, and we are eager to maximize its potential." 

About H2-Pharma, LLC

H2-Pharma LLC is a privately-held pharmaceutical company focused on the sales, marketing and development of brand and generic products. With 45 years in the industry, H2-Pharma has developed the experience and distribution infrastructure to market and distribute products across the spectrum, combined with a level of personal service that is unmatched in the industry.

Please visit our web-site at www.h2-pharma.com

About CHEPLAPHARM Arzneimittel GmbH

CHEPLAPHARM is a family owned pharmaceutical company with its headquarters situated in Germany and offering branded products on a global level. The company focuses on an internationally oriented Buy and Build Strategy. In close collaboration with its business partners, CHEPLAPHARM generates sustainable annual growth rates.

CHEPLAPHARM specializes in selected active substances and indications and commits itself to provide branded products of high quality and to guarantee continuous availability to its customers.

Please refer to www.cheplapharm.com for additional information.

SOURCE H2-Pharma, LLC


These press releases may also interest you

19 avr 2024
OKX, a leading Web3 technology company, today added support for Runes, a new fungible token standard by Casey Rodarmor, a former Bitcoin developer and artist, following today's Bitcoin halving. With this addition, users can now create, mint, manage...

19 avr 2024
Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") , a California-based global shared intelligent electric mobility ecosystem company, today announced that it received a letter (the "Nasdaq Letter") from The Nasdaq Stock...

19 avr 2024
Genifi Inc. (formerly Prodigy Ventures Inc.) ("genifi" or the "Company") today announced its financial results for the three months and year ended December 31, 2023. As previously reported, the Company sold TCB Corporation ("Prodigy Labs") on...

19 avr 2024
Sabre Corporation ("Sabre") announced plans to host a live webcast of its 2024 Annual Meeting of Stockholders on April 24, 2024 at 10:30 a.m. ET.  The webcast will be accessible by visiting the Investor Relations section of Sabre's website...

19 avr 2024
Illinois House Speaker Emanuel "Chris" Welch was unanimously recommended to serve as the new Proviso Township Committeeman in a meeting held Friday evening of the Executive Committee, replacing the late Karen Yarbrough....

19 avr 2024
Nium, the global leader in real-time, cross-border payments, and Asia's leading payments, banking, and capital markets research firm, Kapronasia, today launched "Breaking Borders: The Revolution of Real-Time Cross-Border B2B Payments in Asia" - a new...



News published on and distributed by: